Colleen Kusy
Stock Analyst at Baird
(1.64)
# 3,470
Out of 5,132 analysts
50
Total ratings
37.78%
Success rate
-1.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Neutral | $924 → $858 | $821.96 | +4.38% | 1 | Dec 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $100.89 | +56.61% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $36.53 | -6.93% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $21.70 | +139.63% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $8.88 | +170.27% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $5.67 | +58.73% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $26.72 | +94.61% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $2.92 | +105.48% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $28.49 | +43.91% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.61 | +272.67% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $36.63 | +77.45% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $9.99 | +150.25% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.58 | +2,347.55% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.57 | +1,222.96% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.85 | +5,874.03% | 1 | Nov 2, 2021 |
argenx SE
Dec 18, 2025
Downgrades: Neutral
Price Target: $924 → $858
Current: $821.96
Upside: +4.38%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $100.89
Upside: +56.61%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $36.53
Upside: -6.93%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $21.70
Upside: +139.63%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $8.88
Upside: +170.27%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $5.67
Upside: +58.73%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $26.72
Upside: +94.61%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $2.92
Upside: +105.48%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $28.49
Upside: +43.91%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.61
Upside: +272.67%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $36.63
Upside: +77.45%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.99
Upside: +150.25%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.58
Upside: +2,347.55%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.57
Upside: +1,222.96%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.85
Upside: +5,874.03%